Tag
ProPublica’s massive investigation into the hefty fees pharmaceutical companies have paid doctors with dubious track records stamps an exclamation point…
•
It hasn’t had quite as much impact as some earlier health-related recession trend stories, but the rise in prescription abandonment…
•
Midwest Health Journalism Program fellow Jim Doyle, a reporter at the St. Louis Post-Dispatch, tells the story of Forest Pharmaceuticals…
•
First, the background: Avandia, also known as rosiglitazone, is an anti-diabetes drug that helps patients control their blood sugar. It…
•
Medical Marketing & Media‘s Marc Iskowitz profiles a new continuing medical education provider, Lighthouse Learning. Started by a Harvard neurologist…
•
Writing for Mother Jones, University of Minnesota medical ethics professor Carl Elliott digs into the Dan Markingson story first covered…
•
Thanks to new requirements, the FDA is now publishing updates on its safety evaluations of drugs that are already on…
•
In the wake of questions about GlaxoSmithKline’s Avandia clinic trials, the Austin American-Statesman‘s Ana Cantú talks about her own experience…
•
FairWarning’s Lea Yu and The New York Times‘ Gardiner Harris drew our attention to a report from the HHS Office…
The Health Policy law will require drug makers to disclose the amounts of free samples they distribute, a requirement which…